Nurix Therapeutics (NRIX)

Executive Summary

Nurix Therapeutics is a clinical-stage biopharmaceutical company pioneering targeted protein degradation therapies for cancer and autoimmune diseases. The company's proprietary platforms—including degrader molecules and Deubiquitinase Targeting Chimeras (DACs)—enable selective modulation of protein levels. Lead program NX-5948, an oral BTK degrader, has demonstrated encouraging safety and efficacy in heavily pretreated B-cell malignancies, including chronic lymphocytic leukemia (CLL), with Phase 1 data showing durable responses. NX-2127, another BTK degrader, is also in Phase 1 for CLL and related lymphomas. Additionally, NX-1607, a CBL-B inhibitor targeting immune evasion, is being evaluated in solid tumors both as monotherapy and in combination with checkpoint inhibitors. With a robust pipeline and a strong cash position, Nurix is positioned to deliver multiple clinical readouts over the next 12-18 months, potentially validating its platform and driving significant value.

Upcoming Catalysts (preview)

• Q2 2027NX-5948 Phase 2 interim data in CLL/SLL60% success
• Q4 2026NX-1607 Phase 1/2 data update in solid tumors55% success
• H1 2026NX-2127 Phase 1 dose-expansion data in CLL65% success